▲Wirig Diagram Hot
▲ ▲ ▼

Understanding Clear Cell Papillary Renal Cell Tumor: Is It Cancer?

By

Clear cell papillary renal cell tumor (CCPRCT) is a distinct entity in the kidney's comprehensive tumor spectrum. It's important to distinguish CCPRCT from other renal cell carcinomas due to significant differences in management approaches and patient prognosis. Let's dive into the details, understanding what CCPRCT is, its characteristics, diagnosis, and treatment.

First, let's shed some light on the terminology. Renal cell carcinoma (RCC) is a common type of kidney cancer. CCPRCT, first recognized in 2010, is a specific subtype of RCC, characterized by distinctive features that set it apart from other subtypes.

CCPRCT: Definition and Classification

CCPRCT is defined by the World Health Organization (WHO) as a biphasic tumor composed of clear cells and papillary cystic or tubulopapillary structures. This unique architecture is what gives CCPRCT its name.

Chromophobe
Chromophobe
an image of some pink cells
an image of some pink cells
Papillary Left Renal Cell Carcinoma
Papillary Left Renal Cell Carcinoma

In the original classification, CCPRCT was grouped under the collecting duct carcinoma category. However, given its distinct features and behavior, it is now recognized as a unique entity in the 2016 WHO classification of renal tumors.

Histological Features

Histologically, CCPRCT is characterized by typical clear cells, which are large, round-to-oval,야 Winchester, anslow cubic cells with abundant glycogen. These cells are nested or arranged in solid nests within a fibromyoadipose stroma. The papillary or tubulopapillary structures are lined by small, darker ( Tinted ) cells, which are Alcian blue-positive in many cases.

Renal cell Carcinoma
Renal cell Carcinoma
Renal Cell Carcinoma (RCC) & Pediatric Tumors 🎗️
Renal Cell Carcinoma (RCC) & Pediatric Tumors 🎗️
Kidney Cancer --- Scientists have isolated cancer stem cells that lead to the growth of Wilms’ tumours, a type of cancer typically found in the kidneys of young children. The researchers have used these cancer stem cells to test a new therapeutic approach that one day might be used to treat some of the more aggressive types of this disease. The results are published online in EMBO Molecular Medicine. Renal Tubule Anatomy, Renal Tubule, Microscopic Kidney Tissue Sample, Renal Cell Carcinoma Histology, Development Of Kidney, Medullary Sponge Kidney, Understanding Kidney Structures, Kidney Restoration, Compression Atrophy Of Human Kidney
Kidney Cancer --- Scientists have isolated cancer stem cells that lead to the growth of Wilms’ tumours, a type of cancer typically found in the kidneys of young children. The researchers have used these cancer stem cells to test a new therapeutic approach that one day might be used to treat some of the more aggressive types of this disease. The results are published online in EMBO Molecular Medicine. Renal Tubule Anatomy, Renal Tubule, Microscopic Kidney Tissue Sample, Renal Cell Carcinoma Histology, Development Of Kidney, Medullary Sponge Kidney, Understanding Kidney Structures, Kidney Restoration, Compression Atrophy Of Human Kidney

Immunohistochemistry shows that CCPRCTs are typically negative for cytokeratin 7, CD10, AMACR, and vimentin, with variable expression of was applied together,AMACR, and p504S. This unique immunoprofile further distinguishes CCPRCT from other RCC subtypes.

Clinical Features

CCPRCT tends to present at an older age compared to conventional RCC. It's also more common in women and often presents at an advanced stage. This is an important aspect to consider, as Management strategies and patient outcomes may differ from other RCC subtypes.

ولد harzlia, CCPRCT can be asymptomatic and incidentally diagnosed during imaging for other conditions. However, it can also cause symptoms like hematuria, flank pain, or a abdominal mass. metastatic disease can lead to additional symptoms like weight loss, fever, or bone pain.

Papillary Renal Cell Carcinoma (RCC) Left Kidney and Hepatic Hemangioma
Papillary Renal Cell Carcinoma (RCC) Left Kidney and Hepatic Hemangioma
Renal Cell Carcinoma Treatment Journey: From Diagnosis to Recovery
Renal Cell Carcinoma Treatment Journey: From Diagnosis to Recovery
What is Renal Cell Carcinoma and How Is It Treated?
What is Renal Cell Carcinoma and How Is It Treated?
The Effects of Metastatic Renal Cell Carcinoma on the Body
The Effects of Metastatic Renal Cell Carcinoma on the Body
What Is Chromophobe Renal Cell Carcinoma?
What Is Chromophobe Renal Cell Carcinoma?
The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma (05.09.2016)
The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma (05.09.2016)

Diagnosis and Staging

Most CCPRCTs are diagnosed through imaging techniques such as computed tomography (CT) scans and magnetic resonance imaging (MRI). However, the golden standard for diagnosis iscore markers, pathology confirmation through core needle biopsy or surgery.

Staging of CCPRCT follows the TNM staging system, similar to other RCC subtypes. However, since CCPRCT often presents at an advanced stage, management strategies may need to be more aggressive, and life expectancy considerations differ from other RCC subtypes.

Treatment Options

The mainstay of treatment for early-stage CCPRCT is surgical resection in the form of partial nephrectomy or radical nephrectomy, depending on tumor size and invasion. Nephron-sparing surgery is preferred when technically feasible, given its benefits in preserving renal function.

Targeting and dissociating HIF2α from the molecular chaperone Hsp70 triggers apoptosis in kidney cancer - Communications Medicine
Targeting and dissociating HIF2α from the molecular chaperone Hsp70 triggers apoptosis in kidney cancer - Communications Medicine

For advanced or metastatic CCPRCT, systemic therapy is recommended. Targeted agents like tyrosine kinase inhibitors have shown promise in treating metastatic RCC. Antibodies against programmed death receptor-1 (PD-1) and its ligand (PD-L1) have also demonstrated efficacy in some cases. However, more clinical trials are needed to establish optimal treatment strategies for CCPRCT.

Prognosis and Survival

Prognosis for CCPRCT patients is generally worse than for patients with other RCC subtypes, due to its advanced stage at presentation and higher-grade features. The 5-year overall survival rate is estimated to be around 50-60%, although this can vary greatly depending on individual disease characteristics and treatment response.

Regular follow-ups with imaging and clinical assessments are crucial to monitor for recurrence and manage this complex disease. Prognosis considerations should include not only cancer-specific survival but also overall survival, quality of life, and long-term impacts on renal function and other comorbidities.

To wrap up, clear cell papillary renal cell tumor is a unique subtype of RCC that deserves special attention in clinical practice. Its distinctive features, clinical course, and treatment requirements necessitate continued research and dialogue among healthcare providers. If you or someone you know has been diagnosed with CCPRCT, remember that early diagnosis, tailored management, and regular follow-ups are key to navigating this complex cancer journey.

💬 Comments ↗ Share ★ Save
AD